Since our founding in 1934, the Rosell® Institute for Microbiome and Probiotics has been committed to scientific innovation. Our areas of research focus on the fermentation and bacteria strain improvement processes including factors that influence the technological performance of our strains.
As a leader in the investigation, development, and application of living microorganisms, we have implemented different research programs focused on better understanding the properties, mechanisms, and effects of probiotics on human health. We have forged alliances and collaborative relationships with international public and private partners, which include universities, hospitals, and world-renowned research centers some of which include:
• McGill University
• Université de Montréal
• University of Saskatchewan
• The Agriculture and Agri-Food Canada Food Research and Development Centre
• The National Research Council Biotechnology Research Institute
• INRA Toulouse
• Sapienza Universita di Roma
• University of New South Wales
• The Assistance Publique Hôpitaux de Paris
• CHU Louis-Mourier
• CHU Nice
• CHU Rouen
• The University of Milan
• Biofortis Nantes
• The Hospital for Sick Children affiliated with the University of Toronto
In 1998, the Rosell® Institute was acquired by Lallemand Inc. which paved the way for exciting new research opportunities that focused on the scientific and clinical documentation of probiotic formulations to benefit health.alth .
The principal offerings of the Rosell® Institute consist of scientifically documented products based on probiotic strains derived primarily from the Rosell® collection. These products include Lacidofil®, Probiokid®, and Probio’stick® formulations, among others and include specific strains under the Rosell® or LAFTI® trademark. They are marketed in numerous countries either as dietary supplements or over-the-counter drugs.
Showing 1 to 2 of 2 (1 Pages)